Substituted spiroheterocycles

US7825110B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Min Xiang · Bound Brook, US
• Mona Patel · Montgomery, US
• Philip Rybczynski · Somerville, US
• Joseph Gunnet · Flemington, US
• Keith Demarest · Flemington, US
• Richard Look · Trenton, US
• Bruce E. Maryanoff · Robinson Township, US
• Michael John Costanzo · Bonney Lake, US
• Stephen C. Yabut · North Wales, US

Key dates

• Filing date: Sep 19, 2007
• Grant date: Nov 2, 2010
• Expiry date: Oct 18, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I,which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.